VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
2.430
-0.190 (-7.25%)
At close: May 1, 2026, 4:00 PM EDT
2.480
+0.050 (2.06%)
After-hours: May 1, 2026, 5:17 PM EDT
VolitionRx Revenue
In the year 2025, VolitionRx had annual revenue of $1.73M with 40.04% growth. VolitionRx had revenue of $447.03K in the quarter ending December 31, 2025, with 133.25% growth.
Revenue (ttm)
$1.73M
Revenue Growth
+40.04%
P/S Ratio
12.02
Revenue / Employee
$23,032
Employees
75
Market Cap
19.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.73M | 493.87K | 40.04% |
| Dec 31, 2024 | 1.23M | 458.21K | 59.10% |
| Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
| Dec 31, 2022 | 306.39K | 292.96K | 2,180.89% |
| Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
| Dec 31, 2019 | 17.10K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TELA Bio | 80.28M |
| IRIDEX | 52.68M |
| Myomo | 40.93M |
| Cytosorbents | 37.06M |
| Lifeward | 22.03M |
| Pulsenmore | 12.55M |
| Picard Medical | 4.94M |
| IceCure Medical | 3.38M |
VNRX News
- 2 days ago - Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing - PRNewsWire
- 8 days ago - VolitionRx Announces Acceptance of Compliance Plan by NYSE American - PRNewsWire
- 11 days ago - Volition Launches rNuQ™ Webshop Broadening Product Range - PRNewsWire
- 4 weeks ago - VolitionRx Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update - PRNewsWire
- 4 weeks ago - VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium - PRNewsWire
- 4 weeks ago - Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients - PRNewsWire
- 5 weeks ago - Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference - PRNewsWire